Back to Search
Start Over
Safety and efficiency modifications of SIV-based integrase-defective lentiviral vectors for immunization.
- Source :
-
Molecular therapy. Methods & clinical development [Mol Ther Methods Clin Dev] 2021 Oct 01; Vol. 23, pp. 263-275. Date of Electronic Publication: 2021 Oct 01 (Print Publication: 2021). - Publication Year :
- 2021
-
Abstract
- Integrase-defective lentiviral vectors (IDLVs) represent an attractive platform for vaccine development as a result of the ability to induce persistent humoral- and cellular-mediated immune responses against the encoded transgene. Compared with the parental integrating vector, the main advantages for using IDLV are the reduced hazard of insertional mutagenesis and the decreased risk for vector mobilization by wild-type viruses. Here we report on the development and use in the mouse immunogenicity model of simian immunodeficiency virus (SIV)-based IDLV containing a long deletion in the U3 region and with the 3' polypurine tract (PPT) removed from the transfer vector for improving safety and/or efficacy. Results show that a safer extended deletion of U3 sequences did not modify integrase-mediated or -independent integration efficiency. Interestingly, 3' PPT deletion impaired integrase-mediated integration but did not reduce illegitimate, integrase-independent integration efficiency, contrary to what was previously reported in the HIV system. Importantly, although the extended deletion in the U3 did not affect expression or immunogenicity from IDLV, deletion of 3' PPT considerably reduced both expression and immunogenicity of IDLV.<br />Competing Interests: The authors declare no competing interests.<br /> (© 2021 The Author(s).)
Details
- Language :
- English
- ISSN :
- 2329-0501
- Volume :
- 23
- Database :
- MEDLINE
- Journal :
- Molecular therapy. Methods & clinical development
- Publication Type :
- Academic Journal
- Accession number :
- 34729374
- Full Text :
- https://doi.org/10.1016/j.omtm.2021.09.011